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Abstract
Background—We previously reported results of a randomized, placebo-controlled study of egg 
oral immunotherapy (eOIT), in which 27.5% of subjects achieved sustained unresponsiveness 
(SU) after 2 years. Here we report results of treatment through 4 years and long-term follow-up.
Objective—To evaluate the efficacy and safety of eOIT in participants treated up to 4 years.
Methods—Egg-allergic children (5–18 y/o) received eOIT (n=40) for up to 4 years or placebo 
(n=15) ≤1 year. The key outcome was the percentage of subjects achieving SU by Year 4. Safety 
and immunologic assessments were performed, and long-term follow-up questionnaires were 
administered after study conclusion (LFQ-1) and 1 year later (LFQ-2).
Results—Of 40 eOIT-treated subjects, 20/40 (50.0%) demonstrated SU by Year 4. For those 
subjects still dosing during Years 3–4, mild symptoms were present in 12/22 (54.5%) subjects. At 
the time of LFQ, more eOIT subjects [LFQ-1 23/34 (68%); LFQ-2 21/33 (64%)] were consuming 
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unbaked and baked egg vs. placebos [LFQ-1 2/11(18%), p=0.006; LFQ-2 3/12 (25%), p=0.04]. Of 
subjects achieving SU, 18/20 (90%) completed the LFQ with 18/18 (100%) reporting consumption 
of all forms of egg. When compared to subjects not achieving SU, subjects achieving SU had 
higher IgG4 values (p=0.001) and lower egg skin prick test scores (p=0.0002) over time and a 
lower median baseline ratio of egg-specific IgE to total IgE (1.1% vs. 2.7%, p=0.04).
Conclusions—SU following egg OIT is enhanced with longer duration of therapy, and increases 
the likelihood of tolerating unbaked egg in the diet.
Keywords
egg allergy; food allergy; oral immunotherapy; desensitization; sustained unresponsiveness; 
immune tolerance; immunoglobulin E; follow-up
INTRODUCTION
Egg allergy is common in childhood, with a prevalence ranging from 0.5–2.5%.(1–4) Egg 
and egg-derived products are ubiquitous ingredients; therefore, avoiding accidental 
exposures leading to reactions is difficult.(5) Although the long-term prognosis of egg 
allergy is generally favorable, recent studies have suggested that resolution may occur more 
slowly than was previously appreciated, and a subset of egg allergic patients have egg 
allergy which persists into adolescence.(6, 7) Until and if tolerance develops spontaneously, 
patients are at risk for allergic reactions.
Several approaches to mitigating this risk have been examined in clinical trials. The best-
studied approach is OIT, a procedure that aims to decrease reactivity to allergen with gradual 
escalation of daily doses followed by a maintenance treatment period.(8) Our group 
previously reported that 10 months of treatment with egg OIT (eOIT) was superior to 
placebo when comparing the successfully consumed dose during ongoing therapy (clinical 
desensitization) and that this benefit was enhanced with an additional year of therapy.(9) 
Sustained unresponsiveness (defined as lack of dose-limiting symptoms during an OFC to 
and subsequent open feeding of egg 4–6 weeks after stopping OIT) was achieved in 28% of 
the subjects on eOIT by month 24 with all reporting consumption of egg one year later. The 
results from this trial suggested that OIT may have a long-term disease-modifying effect as 
noted for outcomes assessed during two years of therapy.
Evidence of such an outcome would be a major breakthrough in the development of a food 
allergy treatment. Currently, the stability of treatment effects after such trials are not well 
understood. Two recent studies have provided long-term follow-up data after milk and 
peanut OIT, and both demonstrated that regular oral intake of the allergenic food appears to 
be required in order to maintain the protective effect following OIT but continued intake was 
difficult for some patients to continue.(10, 11) Another study comparing peanut OIT and 
SLIT demonstrated suppression of basophil effector cell function and dendritic cell-driven 
Th2 cytokine responses following peanut OIT, with some reversibility of those responses 
noted when antigen was discontinued in those achieving SU.(12, 13) These studies indicate 
that if allergen is avoided, clinical relapse can ensue, even among individuals previously 
considered to be treatment successes. This situation poses potential safety concerns if such 
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individuals incorrectly believe themselves to be protected.(14) Additional long-term studies 
after OIT treatment are necessary in order to further examine feasibility, safety, and 
durability of the treatment effect.
To investigate the effects of long-term OIT in patients with egg allergy, we continued the 
previously reported trial of eOIT for up to 4 years of treatment.(9) The proportion of 
subjects achieving sustained unresponsiveness in those 4 years was calculated. After the 
treatment phase of the study ended, an annual long-term follow-up questionnaire to assess 
egg consumption patterns was administered.
Materials and Methods
Study design and endpoints assessed
The current study is an extension of a previously published multi-center, randomized, 
double-blind, placebo-controlled study of eOIT.(9) As previously reported, subjects were 
enrolled and treated with placebo or eOIT for 10 months. Placebo-treated subjects were 
discontinued from dosing after 10 months and were followed as treatment controls through 
Year 2 and then surveyed for long-term follow-up. Subjects receiving eOIT continued dosing 
to Year 4 and discontinued dosing after passing an OFC off therapy (i.e., those achieving 
SU) following any yearly challenge point (Years 2, 3 or 4). The key outcome of this study 
was the percentage of subjects with SU to egg after up to 4 years of eOIT. SU was defined as 
lack of dose-limiting symptoms during a 10 gm egg white powder (∼8 grams egg white 
protein) OFC and open feeding to a meal-size portion of whole cooked egg 4–6 weeks after 
stopping eOIT while maintaining an egg restricted diet. Secondary outcomes included safety 
during the additional years of treatment using methods previously reported(9), and 
immunologic assessments. Egg consumption was evaluated after the last subject completed 
the treatment phase by having all available subjects complete a long-term follow-up 
questionnaire, which was repeated approximately 1 year later. Tolerance to baked egg 
consumption was not assessed during the study entry or at any point in the study.
Study Population
Subjects were ages 5–18 years, from 5 US sites with inclusion/exclusion criteria previously 
reported.(9) The study was approved by each site’s institutional review board, and written 
consent/assent was obtained. The study was conducted under an FDA investigational new 
drug application and monitored by an independent data and safety monitoring board from 
the National Institute of Allergy and Infectious Diseases.
Egg OIT dosing and participant follow-up
Dried Standard Egg White powder (raw, uncooked egg) was purchased from a commercial 
manufacturer (Deb-El Food Products) and was manufactured for individual doses for eOIT 
dosing. The daily OIT dose was mixed in a vehicle, such as pudding or applesauce, for 
dosing. Limiting physical activity was recommended for all participants for the first 2 hours 
after OIT dosing. Subjects who attained SU at any challenge point were instructed to 
incorporate egg into their diets ad libitum; however, there were no specific recommendation 
made on frequency, amount, or type of egg product.(9) Subjects who did not develop SU at 
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Year 2 or Year 3 were instructed to continue egg avoidance and to continue open-label 
dosing, per protocol, with 2,000 mg/day of eOIT for up to four years of treatment. Subjects 
who failed the SU OFC resumed eOIT maintenance dosing through dose escalations every 
1–2 weeks beginning with 25% of their maintenance dose or their highest tolerated 
cumulative dose during OFC, whichever was lowest. Subjects who withdrew from dosing for 
any reason other than achieving SU or were originally in the placebo treatment arm were 
instructed to continue dietary avoidance of egg. An exception included one site’s IRB 
mandate to crossover placebo subjects to eOIT treatment after Year 2 as part of a separate 
treatment protocol. Subjects who did not achieve SU after the 4-year study period were 
discontinued from dosing and instructed to continue dietary avoidance. For LFQ analysis, 
subjects were grouped into 4 categories based on their treatment and last known clinical 
outcome status: 1) Egg OIT: SU, 2) Egg OIT: desensitized, 3) Egg OIT: not-desensitized, 
and 4) Placebo.
Oral food challenge (OFC) assessment
At Years 2, 3 and 4, all subjects treated with eOIT underwent a 10 gm (cumulative dose) 
OFC to egg white powder to assess desensitization, i.e., the ability to consume egg while on 
OIT. Those who passed the desensitization OFC discontinued OIT dosing for 4–6 weeks and 
had a second (10 gm) OFC, followed by a 10 gram open egg feeding, to assess for SU, as 
previously reported.(9) The food challenge dose was mixed in a vehicle, typically pudding 
or applesauce, for dosing.
Long-term Follow-up Questionnaire
A scripted 25-item LFQ was administered twice (LFQ-1 after the last subject completed 
dosing and study OFCs; LFQ-2 approximately 1 year later). This survey (see On-line 
Repository) captured patterns of unbaked and baked egg consumption in egg eOIT 
participants and those previously treated with placebo OIT. In the LFQ, unbaked egg 
products referred to scrambled eggs, fried eggs, raw eggs, undercooked eggs, French toast or 
custard; baked egg products referred to cakes, muffins, and waffles. Subjects were asked to 
rate the frequency of symptoms to various forms of egg ingested to assess consumption 
patterns and adverse symptoms.
Assessment of Immunologic Markers/Mechanisms
Immunologic mechanisms were assessed during the study as previously described.(9) Skin 
prick testing (SPT), serum egg-specific IgE and IgG4 antibody levels, and basophil 
activation studies were performed at 6-month intervals through the end of the study (Year 4). 
Endpoint titration SPT was performed at Year 4 by measuring SPT wheal size using 5 serial 
weight/volume egg extract dilutions using commercially available egg white extract from 
Greer Laboratories (1:20, 1:200, 1:2,000, 1:20,000, 1:200,000).(15)
Statistical Methods
The study design was previously described(9) and, in brief, was adequately powered to 
compare the placebo arm to the eOIT arm for the primary endpoint (i.e., at 2 years) but was 
not specifically designed to ensure power for long-term comparisons of interest. The key 
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outcome of interest for the extension phase was the cumulative proportion of eOIT subjects 
achieving SU through 4 years. The proportion of eOIT subjects who did not achieve SU at 2 
years but did achieve SU when treated after 2 years was also estimated. Comparisons of 
interest for immunologic assessments were between eOIT subjects achieving SU and those 
who did not. Differences between groups in continuous variables were assessed using exact 
Wilcoxon rank sum tests where computationally possible and the asymptotic Wilcoxon rank 
sum p-value in all other cases. Egg endpoint titration area under the curve was calculated as 
the sum of the wheal scores at each of the 5 serial weight/volume egg extract dilutions and 
assessed using the Wilcoxon rank sum test. Basophil activation, immunoglobulin levels, and 
SPT wheal scores were each evaluated in repeated-measurement models, with the baseline 
value, study visit, and SU status at Year 4 as covariates and heterogeneous compound 
symmetry within-person covariance. Hypothesis testing was performed using the log 10 
transformation for IgE and IgG4 while summary statistics are reported on the observed 
scale. For the LFQ, analysis was primarily descriptive although differences between original 
treatment groups (placebo versus eOIT) in proportions of categorical variables were 
evaluated using Fisher’s Exact test and in continuous variables using the Wilcoxon rank sum 
test. Logistic regression was used to identify baseline and Week 44 clinical and mechanistic 
factors (log transformed where noted) that might identify SU. All analyses were performed 
with the use of SAS software, version 9.2 (SAS Institute).
Results
Study Population
Fifty-five subjects enrolled initially (Figure 1); 6/40 (15%) eOIT and 2/15 (13.3%) placebo 
subjects withdrew from dosing before 24 months; one eOIT subject withdrew after 24 
months, but prior to resuming dosing; 8 additional eOIT subjects withdrew from dosing after 
24 months, before the end of study at Year 4 (see Table S1 in Online Repository). One of 
these subjects was withdrawn at month 30 for non-compliance due to regular whole egg 
consumption prior to passing any study OFC.
Sustained unresponsiveness is enhanced with duration of eOIT dosing
As previously reported, 0/15 (0%) placebo and 22/40 (55%) eOIT subjects were desensitized 
to 5 grams of egg white powder after 10 months of therapy, and 30/40 (75%) of eOIT 
subjects were desensitized to 10 grams of egg white powder after 22 months of therapy.(9) 
The number of eOIT subjects attaining desensitization reached 31/40 (77.5%) at Years 3 and 
4 (Table 1). SU at Year 2 occurred in 11/40 (27.5%) of eOIT subjects(9) and increased to 
18/40 (45.0%) in Year 3 and 20/40 (50.0%) in Year 4. Among the 22 eOIT subjects on 
treatment after Year 2, 41% achieved SU by Year 4. Logistic regression identified no 
baseline clinical features (e.g., age, atopic dermatitis, asthma, etc.) as significantly predictive 
of SU at Year 4.
Long-term OIT dosing induces mild symptoms in a majority of subjects
Symptoms reported during long-term egg OIT dosing—Of 22 subjects on eOIT in 
Years 3–4, 12 (54.5%) experienced symptoms with dosing, all categorized as mild (see Table 
S2 in Online Repository for symptoms scoring). Three subjects (13.6%) reported oral/
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pharyngeal symptoms only; 9 (40.9%) reported skin, respiratory, or GI symptoms; 6 subjects 
(27.3%) were treated. Of 8,925 doses administered, 95% (8482 doses) were symptom-free 
(Table 2). Only 1.9% of doses resulted in symptoms lasting >30 minutes reported during 
home dosing; 1.6% of doses required treatment with antihistamines during either clinic (2 
doses) or home dosing (144 doses). None required treatment with epinephrine for dosing-
related symptoms during Years 3–4. Three subjects received 1 dose of epinephrine each 
during OFCs assessing SU. Dosing symptoms prior to and after Year 2 were summarized 
among the 22 subjects with eOIT dosing after Year 2. Prior to Year 2, the median percent of 
doses per subject with any symptoms was 8.0% for these 22 subjects. After Year 2 the 
median percent of doses per subject was 0.2% for these same 22 subjects, representing a 
reduction in dosing symptoms after Year 2 of the study.
Pre-Week 44 dosing reactions predictive of SU
We examined pre-Week 44 dosing reactions to determine if early dosing reactions were 
associated with long term clinical outcomes (see Table S3 in Online Repository). Reactions 
were compared between eOIT subjects achieving SU and all other eOIT subjects. The only 
statistically significantly difference was in the percentage of doses with moderate symptoms 
per subject (Wilcoxon p=0.03). Subjects with no moderate symptoms prior to Week 44 were 
significantly more likely to achieve SU by Year 4 compared to subjects who had any 
moderate symptoms in that time period (logistic regression p=0.047, OR=4.64, 95% CI: 
1.02, 21.00) (see Table S4 in Online Repository).
Food allergy episodes (FAEs) and unsolicited adverse events (AEs) during 
Years 3–4—Thirty-five FAEs (food-induced reactions not related to study product) 
occurred in eOIT subjects in Years 3–4 with only 3 egg-related. Two occurred in eOIT 
desensitized subjects with symptoms of mouth/throat itching; one treated with 
antihistamines only. One reaction included abdominal pain and vomiting requiring 
epinephrine after the subject consumed lightly cooked egg, without any precipitating triggers 
(such as fever, viral infection, or exercise). This subject had achieved SU 19.4 months prior 
and subsequently reported on their LFQs unrestricted, asymptomatic egg consumption of 
baked and unbaked egg several times per week . A total of 141 AEs (events that were not 
dosing symptom/OFC related) were reported in 21/22 subjects during Years 3–4 of eOIT 
dosing, mostly MedDRA® categorized as System Organ Class Infections/infestations 
(40.4%). AEs were predominantly mild (95.7%) with 6 (4.3%) moderate.
Long-term follow-up questionnaire suggests persistence of SU after treatment cessation
Forty-five of 55 subjects (82%) completed the LFQ-1 and LFQ-2 (see Table S5 in Online 
Repository). The LFQ-1 was completed for eOIT and placebo subjects, respectively, a 
median of 61.7 (IQR: 57.0, 64.7) and 58.5 (IQR: 56.6, 65.6) months after study enrollment 
(p=0.74), 15.6 (IQR: 9.9, 26.1) and 37.1 (IQR: 34.4, 39.4) months after the last clinic visit 
(p<0.001), and at a median age of 12.3 (IQR: 11.2, 13.7) and 13.0 years (IQR: 10.7, 14.0)
(p=0.93).
SU following OIT is associated with higher rates of successful egg 
consumption when compared to other treatment groups—During both LFQ 
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periods, a significantly higher proportion of eOIT subjects reported consumption of unbaked 
and baked egg compared to placebo subjects, potentially driven by those achieving SU 
(Tables 3 and 4). However, when considering dietary consumption of any form of egg 
(unbaked or baked), only during the LFQ-1 were eOIT subjects significantly different than 
placebo subjects (p=0.007) (Table 3).
Of eOIT subjects achieving SU, 18/18 (100%) surveyed reported dietary consumption of all 
forms of egg in LFQ-1 and LFQ-2, while only 4/9 (44%) in LFQ-1 and 2/8 (25%) in LFQ-2 
of eOIT desensitized subjects and 1/7 (14%) in both LFQ-1 and LFQ-2 of eOIT not-
desensitized subjects consumed unbaked egg (Table 4). Overall, eOIT subjects achieving SU 
reported increased frequency and amount of egg consumption in all forms when compared 
to other outcome groups (Table 5; Figure 2; Table S6 in Online Repository). Of subjects 
achieving SU, 3/18 (17%) had increased frequency of symptoms with egg consumption 
between LFQ-1 and LFQ-2, and 1/18 (6%) had symptom reduction. Three subjects at LFQ-1 
and 4 subjects at LFQ-2 with SU reported symptoms after ingesting unbaked egg; 3 had 
increased symptoms to unbaked egg at LFQ-2 compared to LFQ-1, and one had decreased 
symptoms to unbaked egg. One subject with SU reported asymptomatic baked egg 
consumption in LFQ-1 but increased symptoms with baked egg consumption during LFQ-2. 
The longest period of time (median) that subjects achieving SU reported going without 
consuming unbaked egg was 14 days (IQR: 5, 21) in LFQ-1 and 14 days (IQR: 5, 14) in 
LFQ-2 and without consuming baked egg was 5.5 days (IQR: 2, 14) in LFQ-1 and 3.5 days 
(IQR: 2, 7) in LFQ-2. For eOIT subjects not achieving SU and those who were placebo-
treated, dietary restriction of egg was variable, and successful dietary egg consumption in 
any form was reported at a lower frequency and lesser amount consumed than among 
subjects with SU (Tables 4 and 5; Figure 2).
Immunologic data over time
Mechanistic data were compared between subjects achieving SU and those who did not both 
at Year 4 specifically and over time. At Year 4, only egg SPT score (median: 3.0 vs. 7.0 mm, 
p=0.04) and endpoint titration SPT area under the curve (median: 3.5 vs. 11.0 mm, p=0.01) 
were significantly changed in subjects achieving SU at Year 4 (Figure 3; see Table S7–9 and 
Figure S1 in Online Repository). A repeated measures analysis was performed to examine 
whether there was a difference in immunologic values over time, after adjusting for baseline 
value and study visit, between subjects who reached SU and those who did not. Over time, 
egg IgG4 values were significantly greater in those achieving SU (p=0.001). Similarly, egg 
SPT scores were significantly lower in those achieving SU (p=0.0002). For egg IgE and 
basophil activation, there was a decrease over time in those achieving SU; however, the 
differences were not significant and therefore did not discriminate between those achieving 
SU and those who did not.
Immunologic predictors of SU
The baseline median egg-specific IgE level was lower, but statistically insignificant, in 
subjects achieving SU compared with those who did not (9.4 kUA/L vs. 18.5 kUA/L, 
p=0.07). Median percent egg IgE at baseline (i.e., the proportion of egg specific IgE to total 
IgE multiplied by 100) was significantly lower in subjects with SU (1.1% vs. 2.7%, p=0.04); 
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however, logistic regression analysis was not statistically significant [OR=0.89, 95% CI 
(0.78, 1.01), p=0.072]. Logistic regression of mechanistic outcomes identified baseline 
log10 egg IgE [OR=0.21, 95% CI (0.04, 0.99), p=0.049], Week 44 log10 egg IgG4 
[OR=5.48, 95% CI (1.23, 24.38), p=0.026], and Week 44 log10 egg IgG4/IgE [OR=4.62, 
95% CI (1.34, 15.84), p=0.015] as statistically significantly predictive of SU at Year 4; 
however, the area under the curve (AUC) for each model was below 0.75 (log 10 baseline 
egg IgE, AUC=0.67 (95% CI: 0.50, 0.84),Week 44 log 10 IgG4, AUC=0.71 (95% CI: 0.53, 
0.88), and Week 44 log10IgG4/IgE, AUC=0.74 (95% CI:0.59, 0.90)) indicating limited 
utility as a predictor of treatment response.
Discussion
Numerous single- and multi-center studies have shown a beneficial impact of OIT on 
allergic responses in food allergic children including short-term protection for allergen 
desensitization and longer term benefits, such as SU.(9–11, 16–25) However, studies have 
suggested that long-lasting effects of therapy are unlikely without ongoing antigen exposure 
and that the effects of therapy may even be transient, highlighting the potential risk for 
relapse if allergen exposure is not maintained.(10–14, 26)
We previously reported successful desensitization in egg allergic children that improved in 
subjects from Year 1 (55%) to Year 2 (75%) on eOIT.(9) A smaller subset of subjects 
(27.5%) developed SU after discontinuing daily OIT treatment.(9) In this treatment 
extension and long-term follow-up study, we show improvements in achieving SU with 
continued eOIT with 45% in Year 3 and 50% in Year 4. This outcome may be comparable or 
slightly higher to rates of natural egg allergy resolution reported as 12–37% in a similar age 
group.(6) Findings are similar to those published for an open-label peanut OIT study in 
which 50% of subjects attained SU after 5 years of therapy(11) and slightly higher than 
reported in a milk OIT trial in which 40% of subjects achieved SU after 15 months of OIT.
(10) In a more recent, shorter duration study comparing peanut OIT and SLIT, 3/11 (27%) 
OIT subjects attained SU after 18 months of therapy.(13)
Wide-scale clinical application of OIT has been hindered by reports of undesirable allergic 
side effects in randomized trials. In this study, we report long-term safety in Years 3 and 4 of 
eOIT dosing. Mild symptoms were noted in 54.5% of subjects during dosing with none 
reporting moderate or severe symptoms. During follow-up, one eOIT subject reported 
anaphylaxis after consuming unbaked egg 19.4 months after achieving SU. Subsequently, 
the subject was able to resume ad libitum egg consumption of both unbaked and baked egg 
without limitations and without symptoms as reported on long-term follow-up 
questionnaires. Interestingly, during Years 1–2 of eOIT dosing, 15% of eOIT subjects 
withdrew mostly due to dose-related symptoms (predominantly gastrointestinal),(9) a 
finding that was not present during Years 3–4. Participants did require unscheduled visits 
and staff phone calls for advice during illness, further highlighting the importance of close 
monitoring and staff availability during OIT.
This is the first multi-center OIT study to comprehensively survey allergen consumption and 
symptoms for up to 4 years of treatment and following study completion via an annual 
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questionnaire. Overall, 100% of subjects achieving SU were able to consume unbaked egg in 
their diet. As noted in the results section, only one case of anaphylaxis (due to unbaked egg) 
was noted in a subject with SU; however, that subject continued to consume unbaked egg in 
their diet without issues afterward. This finding in the SU treatment group was in direct 
contrast to other eOIT and placebo treatment groups which demonstrated an overall inability 
to consistently consume unbaked egg. When comparing baked egg consumption among 
treatment groups, all eOIT and placebo groups were able to incorporate some amount of 
baked egg into their diets by the second questionnaire; however, the group achieving SU was 
able to consume baked egg without limitations more frequently and in higher amounts.
Despite instructions to remain on an egg-free diet, placebo subjects or eOIT subjects who 
did not attain SU reported unbaked and baked egg consumption with many also reporting 
symptoms with consumption. This difference in recommended diets and the lack of systemic 
evaluation of placebo subjects is unfortunately a clear source of bias, as it is possible that if 
systematically challenged, more placebo treated subjects would be able to tolerate baked or 
unbaked egg than we found here. Full resolution of egg allergy in 2/12 (17%) placebo 
subjects and partial improvement in dietary egg consumption in 7/12 (58%) placebo subjects 
was noted by the second follow-up questionnaire (though one of these were on open-label 
egg OIT in another study protocol), suggesting the potential for underestimation of the 
impact of natural history.(6) In fact, at the time of the second questionnaire, there was no 
longer a significant difference in the inclusion of any form of egg in the diet between the 
active and placebo treated participants; however, significant differences were noted when 
considering dietary consumption of all forms of egg.
Our results support the hypothesis that administering OIT for 3 to 4 years results in 
enhanced rates of SU when compared to administration for only 2 years. We speculate that 
this effect is due to ongoing immunomodulation in specific T- and B-regulatory processes 
over time, but we cannot rule out the role of natural history in this uncontrolled study. 
Furthermore, ongoing, intermittent dietary allergen exposure may be required to maintain 
SU. Importantly, 17% of those achieving SU reported increased symptoms with variable egg 
consumption from daily to less than monthly, but all reported continued egg consumption, 
indicating that variable consumption may have led to symptoms in these subjects. In 
contrast, another study demonstrated that 100% of peanut OIT subjects treated over 5 years 
maintained symptom-free, ad libitum peanut ingestion while consuming an average of 555 
(range 0–4000) mg/day at a frequency of 3 (range 0–7) times/week.(11) These results 
indicate that continued follow-up of patients with SU is critical to monitor for relapse.
Although multiple studies have indicated that significant immunomodulation is associated 
with positive response to OIT,(9, 11, 19, 24, 27, 28) none of the immune parameters tested 
have been consistently predictive of treatment outcomes. In this study, only egg SPT and 
endpoint titration SPT were different at Year 4 for subjects with SU, and only egg SPT and 
log10 egg IgG4 changed significantly over time. Although baseline log10 egg IgE and Week 
44 log10 egg IgG4 were predictive of SU, the p-values were marginal, unadjusted for 
multiple comparisons, and the AUCs were low, thus we would not consider these immune 
parameters to be strong predictors. Egg-specific immunoglobulin components may provide 
additional predictors for success.(29) In the 5-year peanut OIT study, the baseline ratio of 
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peanut-specific IgE:total IgE and the baseline and end-of-study peanut-specific IgE levels 
were predictive of treatment success.(11) In a recent peanut OIT study, basophil activation 
and dendritic cell-driven Th2 cytokine responses to peanut were reduced in subjects 
achieving SU after only 18 months of treatment; however, these parameters reversed in the 
majority of subjects after OIT was discontinued and were not defined predictors of treatment 
success.(12) Our findings and interpretations are limited by the small size of the study. 
Further work is needed to identify biomarkers reliably predictive of a successful treatment 
response to OIT.
This study has several limitations. First, the initial placebo treatment in this study lasted only 
10 months without subsequent food challenges; therefore, the long-term efficacy and safety 
parameters reported are not controlled. Second, as noted in our first report, the study 
population was enrolled based on egg allergy criteria that would predict persistence of 
allergy past 2 years of treatment even though the ability to predict is limited because the 
subjects did not have a baseline OFC. Thus, natural history may play a role in this long-term 
analysis. This study was not adequately controlled to assess spontaneous resolution of egg 
allergy; however, we feel that the majority of a group of children included with elevated egg-
specific IgE and history of egg allergy at enrollment are unlikely to develop tolerance 
naturally. Participants were also not assessed for reactivity to baked egg at baseline, so some 
might have been baked egg tolerant at study entry. Third, due to the expanding numbers of 
OIT subjects achieving SU and subject drop out over the 4-year assessment period, the 
number of participants left to fully evaluate immunologic parameters was small. Thus, the 
end-of-study analysis is likely underpowered to detect differences that may exist. Finally, the 
long-term questionnaire data is based on recall reporting rather than prospective longitudinal 
data collection.
In summary, we demonstrate that the likelihood of SU to eOIT is enhanced with therapy 
exceeding 2 years with those achieving SU demonstrating an increased likelihood of 
tolerating unbaked egg in their diet compared to those who did not achieve SU. Half of 
eOIT-treated subjects achieved SU by Year 4, a treatment response that may require 
ongoing, intermittent dietary egg exposure to be maintained. For the majority of subjects, 
eOIT was administered with mild symptoms reported throughout the study. Extensive 
longitudinal immune evaluation did not identify biomarkers consistently predictive of 
treatment success. Future trials should focus on expansion of study population size and 
diversity of subjects with attention to immunologic assays that can help to personalize OIT 
to enhance predictable success.
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Refer to Web version on PubMed Central for supplementary material.
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Key Messages
• Longer duration of treatment with eOIT is associated with enhanced clinical 
response and increased likelihood of tolerating unbaked egg.
• Mild symptoms are commonly encountered throughout OIT treatment.
• Immune parameters studied do not consistently predict treatment response.
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Figure 1. Study enrollment, randomization and treatment outcomes through Year 4
Greyed boxes represent participants achieving sustained unresponsiveness (SU).
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Figure 2. Long Term Follow-up Questionnaire (LFQ-2): Frequency and Amount of Egg 
Consumption by Treatment Outcome Status
Panel A. Frequency of eating unbaked egg. The percentage of subjects who were eating 
unbaked egg several days per week or more: Egg OIT–SU=61%, Egg OIT-D=25%, Egg 
OIT-Not-D=0%, Placebo=17%*. The percentage of subjects who were not eating unbaked 
egg: Egg OIT–SU=0%, Egg OIT-D=75%, Egg OIT-Not-D=86%, Placebo=67%.
Panel B. Amount of unbaked egg eaten at one time. The percentage of subjects who were 
eating a full serving or more of unbaked egg: Egg OIT–SU=83%, Egg OIT-D=13%, Egg 
OIT-Not-D=0%, Placebo=8%.
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Panel C. Frequency of eating baked egg. The percentage of subjects who were eating baked 
egg several days per week or more: Egg OIT–SU=89%, Egg OIT-D=88%, Egg OIT-Not-
D=29%, Placebo=33%**.
The percentage of subjects who were not eating baked egg: Egg OIT–SU=0%, Egg OIT-
D=13%, Egg OIT-Not-D=57%, Placebo=42%*.
Panel D. Amount of baked egg eaten at one time. The percentage of subjects who were 
eating 1 or more of baked egg goods: Egg OIT–SU=94%, Egg OIT-D=88%, Egg OIT-Not-
D=29%, Placebo=50%**.
*One Placebo subject enrolled in an egg OIT study after completing LFQ-1 and consumes 
egg white powder daily but does not consume baked egg.
**One Placebo subject crossed over to egg OIT treatment per their site’s IRB requirement 
after 2 years on study and consumes half a serving of concentrated egg less than monthly 
and 1 baked egg product daily.
Jones et al. Page 18
J Allergy Clin Immunol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Jones et al. Page 19
J Allergy Clin Immunol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Jones et al. Page 20
J Allergy Clin Immunol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Jones et al. Page 21
J Allergy Clin Immunol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Jones et al. Page 22
J Allergy Clin Immunol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Immune Mechanistic Assessments by Year 4 Treatment Outcome Status for Egg OIT 
Subjects
Panel A. Change in Egg-Specific IgE Over Time; Panel B. Change in Egg-Specific IgG4 
Over Time; Panel C. Change in Egg IgG4/IgE Over Time. Panel D. Change in Egg Skin 
Prick Test Over Time; Panel E. Change in Egg End Point Titration Area Under the Curve 
Over Time. Egg IgG4/IgE was calculated by converting IgG4 level from mgA/L to ng/ml 
and converting IgE level from kUA/L to ng/ml with the formula (IgG4 × 1000/IgE x 2.4). 
Egg End Point Titration Area Under the Curve was calculated by adding together the scores 
from all 5 dilutions. Graphs designate “Success” as those subjects treated with egg OIT who 
achieved sustained unresponsiveness versus “Failure” as those subjects treated with egg OIT 
who did not achieve sustained unresponsiveness. Stars represent median values.
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Table 1
Food Challenge Defined Clinical Outcomes with Long-term Egg OIT
Time from Egg OIT
Initiation
Desensitization Sustained
Unresponsiveness
Year 2* 30/40 (75%) 11/40 (27.5%)
Year 3 31/40 (77.5%) 18/40 (45.0%)
Year 4 31/40 (77.5%) 20/40 (50.0%)**
*
Previously reported: Burks, et al. NEJM 2012267:233–43.
**Among the 22 egg OIT subjects treated after 2 years, 41% (95% CI 21%-64%) achieved sustained unresponsiveness; one egg OIT subject who 
failed the 2 year tolerance OFC did not resume egg OIT dosing.
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Table 3
Long-term Follow-up Questionnaire: Egg Consumption by Treatment Group
Egg OIT
N (%) Placebo
*
N (%)
P-value
Eating any egg in diet
  LFQ-1 28/34 (82) 4/11 (36) 0.007
  LFQ-2 28/33 (85) 8/12 (67) 0.22
Eating unbaked and baked egg in diet
  LFQ-1 23/34 (68) 2/11 (18) 0.006
  LFQ-2 21/33 (64) 3/12 (25) 0.04
*
By the time of LFQ-2, two Placebo subjects were receiving egg OIT in other open-label study protocols; one had crossed-over to active OIT at 
Year 2 per their site IRB requirements and was eating unbaked and baked egg for LFQ-1 and LFQ-2; they are included in the group eating any egg 
in diet as well as the group eating unbaked and baked egg in diet for LFQ-1 and LFQ-2. The other subject entered a new study protocol after 
completion of LFQ-1 and was fully restricting egg except for study product eOIT dosing; for LFQ-2 they are included in the group eating any egg 
in diet.
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